

Nanoparticle-based Drug Delivery for Pulmonary Tuberculosis: A Systematic Review on Enhanced Treatment Outcomes, Cellular Uptake, Safety, and Immunomodulatory Potential

Malik Saim Jameel^{a*}, Alveena Mushtaq Malik^b

^aRiphah Institute of Pharmaceutical Sciences, Riphah International University, Lahore Campus, Pakistan

^bFaculty of Pharmacy, University of Central Punjab, Lahore, Pakistan

*Corresponding address: *Riphah Institute of Pharmaceutical Sciences, Riphah International University, Lahore Campus, Pakistan*

Email: maliksaim7845@gmail.com

Received: 20 September 2025 / **Revised:** 18 November 2025 / **Accepted:** 05 December 2025 / **Available Online:** 15 December 2025

ABSTRACT

Objective: This systematic review critically evaluates nanoparticle-based drug delivery systems (NDDS) for pulmonary tuberculosis (TB), emphasizing their therapeutic efficacy, intracellular targeting capabilities, safety, and translational potential via inhalational routes.

Methods: A systematic search of databases, including PubMed, ScienceDirect, Springer, and institutional repositories, was conducted for studies published between January 2013 and December 2024. The Inclusion criteria encompassed nanoparticle formulations targeting *Mycobacterium tuberculosis* via pulmonary delivery with reported in vitro, ex vivo, or in vivo outcomes. Quality and bias were assessed using adapted SYRCLE and Cochrane RoB 2 tools. A total of 15 high-quality studies were selected from 187 records that were initially screened.

Results: Nanoparticles, including metallic (Ag, ZnO), polymeric (PES, mannosylated gelatin), and lipid-based (SLNs, NLCs), demonstrated enhanced drug bioavailability, macrophage uptake, and bactericidal activity against drug-sensitive and multidrug-resistant TB strains. In vivo studies showed superior lung deposition, reduced bacterial load, and minimized systemic toxicity via pulmonary delivery. Functionalization strategies like mannosylation improved intracellular uptake. However, concerns remain regarding nanoparticle cytotoxicity, long-term safety, formulation stability, and inadequate pharmacokinetic profiling.

Conclusion: NDDS for pulmonary TB exhibits significant potential to overcome limitations of conventional therapies by enabling targeted, sustained, and safer drug delivery. Pulmonary and intracellular targeting approaches show strong preclinical efficacy, but translational progress is limited by safety and regulatory gaps. Future research must focus on standardized toxicology, in vivo pharmacokinetics, and clinical trials to establish these platforms as frontline TB therapies.

Keywords: Drug delivery systems; Nanoparticles; Pulmonary drug delivery systems; Tuberculosis; Tuberculosis, Multidrug-resistant

This work is licensed under [Creative Commons Attribution 4.0 International](https://creativecommons.org/licenses/by/4.0/).

Citation: Jameel MS *et al.*, Nanoparticle-based Drug Delivery for Pulmonary Tuberculosis: A Systematic Review on Enhanced Treatment Outcomes, Cellular Uptake, Safety, and Immunomodulatory Potential. J Sci Technol Educ Art Med. 2025;2(2):83-101

Introduction

Tuberculosis continues to be a major global health concern, with an estimated 10.6 million individuals contracting the disease in 2023 and 1.3 million deaths.¹ The disease burden is particularly high in low- and middle-income countries. The emergence of MDR-TB and XDR-TB, with alarmingly low treatment success rates (60% for MDR-TB and 40% for XDR-TB), underscores the urgent need for innovative therapeutic strategies.²

The pathophysiology (Figure 1) of TB involves *Mtb* attacking the alveolar macrophages for survival, disrupting phagosome-lysosome fusion, and forming granulomas.^{3,4} Current TB treatments are prolonged (6–9 months) and often lead to systemic toxicity, poor patient adherence, and inadequate drug concentrations at infection sites.⁵ Nanoparticle (NP)-based drug delivery systems aim to address these issues by enhancing solubility, stability, and targeted delivery of anti-TB drugs to *Mtb*'s primary reservoir, the alveolar macrophages.⁶




Figure 1: Pathogenesis of pulmonary tuberculosis: schematic diagram depicting the various clinical presentations of tuberculosis and their characteristic pathologic mechanisms. Source: Lecturio Medical. Licensed under CC BY-NC-SA 4.0 (<https://creativecommons.org/licenses/by-nc-sa/4.0/>). Original: [paste Lecturio page URL].

For example, pioneering studies demonstrated that inhalable PLGA nanoparticles encapsulating first-line drugs achieved significantly higher drug concentrations in the lungs and alveolar macrophages compared to oral therapy.^{8,9} The versatility of nanocarriers is further highlighted by their application for newer drugs; nanostructured

lipid carriers (NLCs) are recognized as a promising platform for enhancing the delivery of challenging compounds like bedaquiline.^{10,11} Furthermore, NPs facilitate the co-delivery of multiple therapeutics, such as isoniazid with verapamil, reducing *Mtb* survival in macrophages by 95%.¹² Emerging strategies also combine NPs with host-directed

therapies; for instance, nanoparticles co-loaded with multiple drugs have been shown to enhance autophagy in infected macrophages, promoting bacterial clearance in MDR-TB models.¹³⁻¹⁵ Inhaled hyaluronic acid NPs delivering interferon-gamma are being promoted for MDR and XDR-TB patients.^{16,17} These advances highlight nanotechnology's potential to revolutionize TB treatment by addressing pharmacokinetic limitations, overcoming resistance, and improving patient adherence. Figure 2 shows a photomicrograph of silver NPs with antibacterial

activity adapted from Tawfik and Hachim (2014).⁷

Therefore, the objective of this systematic review is to critically evaluate and synthesize recent advancements in nanoparticle-based drug delivery systems for the treatment of pulmonary tuberculosis, with a specific focus on inhalational routes. The study aims to assess the therapeutic efficacy, intracellular targeting capability, formulation safety, and translational feasibility of these nanocarriers, thereby identifying gaps and future directions for clinical application.




Figure 2: SEM micrographs showing the silver nanoparticles in fungal free-cell filtrate appeared as *spherical shape* (arrows) at magnification (x13,000) with a size range between 20 and 70 nm. Reproduced from: *Tawfik M. Muhsin and Ahmad K. Hachim (2014).*⁷

Materials and Methods

Research Strategy

This systematic review was conducted to assess and analyse contemporary evidence on nanoparticle-based therapies delivered via the pulmonary route for tuberculosis (TB) treatment. Comprehensive searches were performed across several public databases and open repositories such as *Nature Reviews Immunology*, *ScienceDirect*, *Springer*, *BMC Infectious Diseases*, *Frontiers in Microbiology*, and institutional sources (e.g., Stellenbosch University repository)

The search strategy combined Medical Subject Headings (MeSH) and free-text keywords related to the core concepts of the review. The primary keywords and their combinations used included:

- Disease Context: ("Tuberculosis" OR "Pulmonary Tuberculosis" OR "Mycobacterium tuberculosis")
- Nanotechnology Intervention: AND ("Nanoparticles" OR "Nanocarriers" OR "Nanoformulations" OR "Nanomedicine" OR "Liposomes" OR "Polymeric Nanoparticles" OR "Solid Lipid Nanoparticles" OR "Inhalable Nanoparticles")

- Delivery Route: AND ("Pulmonary Delivery" OR "Inhalation" OR "Aerosol Delivery" OR "Lung Targeting")
- Therapeutic Aspect (Optional Broadeners): AND ("Drug Delivery" OR "Anti-TB Drugs" OR "Host-Directed Therapy" OR "Drug Resistance")

Selection Criteria

Eligibility for inclusion was limited to English-language publications published between January 2013 and December 2024. Studies were considered eligible if they investigated the development, characterization, or therapeutic evaluation of nanoparticle-based systems specifically targeting *Mycobacterium tuberculosis*. Only those employing pulmonary or inhalational routes of drug administration were included. Furthermore, studies were required to report relevant in vitro, in vivo, or clinical outcomes related to therapeutic efficacy, pharmacokinetics, or safety. Foundational or seminal works published prior to 2013 were also included when deemed critical to the conceptual framework of the review.

Exclusion criteria applied to studies that focused on non-mycobacterial pathogens, such as *Escherichia coli* or *Staphylococcus aureus*, or those that employed non-pulmonary routes of drug delivery, including oral or intravenous administration. Editorials, conference abstracts, and book chapters were excluded due to their lack of peer-reviewed experimental data. Additionally, studies solely addressing diagnostic methods or toxicological screening without a therapeutic component were not considered. Lastly, articles lacking sufficient methodological detail or outcome data were excluded from the final analysis.

Screening and Data Extraction Process

A comprehensive search was conducted across seven major databases and sources to identify relevant studies for this systematic review. These included: PubMed, Scopus, Web of Science, Nature Reviews Immunology, ScienceDirect, Springer, BMC Infectious Diseases, Frontiers in Microbiology, and several open-access institutional repositories such as Stellenbosch University.

From these sources, an initial total of 187 records was retrieved. After careful removal of 63 duplicates and 40 non-research items such as

conference abstracts, editorials, and reviews, 84 records were available for title and abstract screening. Of these 84 studies, 12 records were excluded due to reasons including non-tubercular focus, absence of nanoparticle-based interventions, and irrelevant delivery routes such as oral or intravenous systems. The remaining 72 records proceeded to full-text review for eligibility. Finally, 15 studies were selected that met all the pre-defined inclusion criteria. Figure 3 below gives the PRISMA¹⁸ flowchart used for the selection of studies.

Quality Assessment

The methodological quality and risk of bias of all included studies were critically appraised to ensure the reliability of the synthesized evidence. Given the heterogeneity of the included studies, which comprised both *in-vivo* animal models and *in-vitro* experimental designs, a hybrid approach was adopted based on established systematic review tools.

For *in-vivo* studies involving animal models, the quality was assessed using criteria adapted from the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) Risk of Bias tool.¹⁹ This framework allowed for the systematic evaluation of bias across key domains relevant to animal research, including selection bias e.g., sequence generation, baseline characteristics, performance bias e.g., blinding of personnel, detection bias e.g., blinding of outcome assessment, attrition bias e.g., incomplete outcome data, and reporting bias. For experimental studies, the quality was assessed using criteria adapted from the Cochrane Risk of Bias tool for randomized trials (RoB 2)²⁰, focusing on domains relevant to laboratory-based research. These adapted domains included the clarity of nanoparticle synthesis and characterization, the specification of the *M. tuberculosis* strain, the use of standard antimicrobial assays, the inclusion of cytotoxicity testing, and the transparency of data analysis and presentation.

PRISMA 2020 flow diagram for new systematic reviews which included searches of databases and registers only




Figure 3: PRISMA 2020¹⁸ flow diagram illustrating the process of study identification, screening, eligibility assessment, and inclusion for nanoparticle-based pulmonary tuberculosis therapies.

The authors performed the assessment, with any discrepancies resolved through discussion and consensus. Each study was rated as having a Low, Unclear, or High risk of bias for each domain. A summary of the quality appraisal results, including the specific ratings for each domain, is presented in Table 1. This systematic approach ensures the transparency and methodological rigor of the review, allowing for a more critical interpretation of the evidence.

Table 1: Summary of risk-of-bias assessment for included studies based on adapted SYRCLE¹⁹ and Cochrane RoB 2²⁰ criteria

Study (Author, Year)	Model Type (<i>in vitro</i> , <i>in vivo</i> , <i>ex vivo</i>)	NP Synthesis Clearly Described	<i>M. tuberculosis</i> Strain Specified	Standard Antimicrobial Assay Used	Cytotoxicity Tested	Data Analysis Clearly Presented	Overall Quality (High/Moderate/Low)	Justification/Risk of Bias Note
Singh et al., 2016 ²¹	<i>In vitro</i> & <i>Ex vivo</i> (Macrophage)	Yes (PhytogenicGold-Silver Bimetallic (Au-AgNPs))	Yes (H37Rv, BCG)	Yes (NR, XRMA)	Yes (THP-1, A549, PANC-1)	Yes	High	Very thorough <i>in vitro</i> and <i>ex vivo</i> study, including cytotoxicity and selectivity index.
Agarwal et al., 2013 ²²	<i>In vitro</i>	Yes (Green Synthesis)	Yes (H37Rv, MDR, XDR, MOTT)	Yes (BACTEC 460TB)	No	Yes	Moderate	Strong <i>in vitro</i> data against diverse strains, but a lack of cytotoxicity data is a major limitation for translational focus.
Kalmantaeva et al., 2020 ²³	<i>In vitro</i> & <i>In vivo</i> (Inhalation)	Yes (SNP-PVP, 43.6 nm)	Yes (H37Rv)	Yes (Suspension, CFU counts)	Focus on Immunomodulation/ <i>In vivo</i> Safety	Yes	High	Highly relevant due to the inhalation route and <i>in vivo</i> efficacy/safety data, directly addressing the translational focus. Blinding is not mentioned.
Selim et al.,	<i>In vitro</i>	Yes (Chemical Synthesis, 50	Yes (H37Rv, MDR, <i>M.</i>	Yes (Microplate	No	Yes	Moderate	<i>In vitro</i> only; lacks cytotoxicity/safety

SYSTEMATIC REVIEW

© 2025 Journal of Science Technology Education Art and Medicine

DOI: 10.63137/jsteam.357341



2018 ²⁴		nm)	<i>bovis</i>)	AB assay)				data.
Banu and Rathod, 2013 ²⁵	<i>In vitro</i>	Yes (Biosynthesis, 3-20 nm)	Yes (MDR Clinical Isolates)	Yes (MABA)	No	Yes	Moderate	<i>In vitro</i> only; lacks cytotoxicity/safety data.
Jafari et al., 2016 ²⁶	<i>In vitro & Ex vivo</i> (Macrophage)	Yes (Chemical, 8ZnO/2Ag)	Yes (H37Rv)	Yes (MIC, <i>Ex vivo</i> inhibition)	Yes (THP-1)	Yes	High	Successfully achieved high efficacy and low cytotoxicity in an <i>ex vivo</i> macrophage model, a key translational step.
Heidary et al., 2019 ²⁷	<i>In vitro</i>	Yes (Chemical)	Yes (H37Rv, MDR, XDR)	Yes (MABA, MBC)	Yes (THP-1)	Yes	Moderate	Strong <i>in vitro</i> methodology, but NPs were found to be only bacteriostatic, limiting translational value.
Singh et al., 2015 ²⁸	<i>In vitro & ex vivo</i> (THP-1 macrophage infection model)	Yes (Chemical & Biogenic)	Yes (H37Ra)	Yes. MIC determination, <i>in vitro</i> and <i>ex vivo</i> THP-1 infection model assays.	Yes (THP-1)	Yes	High	Comparative study of synthesis methods; uses <i>ex vivo</i> macrophage model.
Jahagirdar et al., 2020 ²⁹	<i>In vitro & Ex vivo</i> (Macrophage)	Yes (PES Nanoparticles)	Yes (MTB H37Rv)	Yes (MIC, Macrophage infection model)	Yes (RAW 264.7)	Yes	High	Directly addresses intramacrophage delivery with dual drug loading.

SYSTEMATIC REVIEW

© 2025 Journal of Science Technology Education Art and Medicine

DOI: 10.63137/jsteam.357341



Viswanathan et al., 2018 ³⁰	<i>In vitro</i> (Cell Uptake) & <i>In vivo</i> (PK/Efficacy)	Yes (Mannosylated Gelatin NPs)	Yes (MTB H37Rv)	Yes (CFU counts in lung/spleen)	Yes (Acute toxicity study)	Yes	High	Excellent translational study with mannosylation for macrophage targeting and <i>in vivo</i> efficacy in a murine TB model.
Chogale et al., 2021 ³¹	<i>In vitro</i> (Aerosolization) & <i>In vivo</i> (Pulmonary PK)	Yes (Chitosan NPs & RIF Nanocrystals)	No (Focus on formulation/PK)	Not explicitly stated (Focus on formulation/PK)	No (Focus on formulation/PK)	Yes	High	Crucial <i>In Vivo</i> Pulmonary Pharmacokinetics (PK) data; addresses the inhalation route and triple combination therapy.
Pal et al., 2024 ³²	<i>In vitro</i> (Release) & <i>In vivo</i> (Lung Retention)	Yes (Solid Lipid Nanoparticles)	No (Focus on formulation/PK)	Agar diffusion (zone-of-inhibition) assay; MIC calculated from diffusion plates using H37Rv	No (Focus on formulation/PK)	Yes	High	Crucial <i>In Vivo</i> Lung Retention data address the pulmonary delivery of a triple drug combination.
Galdopórpora et al., 2022 ³³	<i>In vitro</i> & <i>In vivo</i> (<i>Wistar rats</i>)	Yes (Soluplus® micelle prep, DLS, 1H-NMR)	Yes (M. tuberculosis H37Rv)	Yes (Microbicidal efficacy in infected macrophages)	Yes (Hemolytic potential, THP-1 viability)	Yes	High	Excellent study directly addressing the pulmonary route with <i>in vitro</i> nebulization and <i>in vivo</i> biodistribution and demonstrating



enhanced efficacy against M. tuberculosis in a relevant cell model.

Vieira et al., 2017 ³⁴	<i>In vitro & Ex vivo (BMDM infection)</i>	Yes (High shear homogenization, Ultrasonication, DLS, TEM)	Yes (<i>M. tuberculosis</i> H37Rv)	Yes (Intracellular growth reduction)	Yes (MTT assay on BMDM)	Yes	High	Strong focus on active targeting to macrophages, which is the cellular reservoir for pulmonary TB. Detailed characterization and clear demonstration of enhanced intracellular efficacy.
-----------------------------------	--	--	-------------------------------------	--------------------------------------	-------------------------	-----	------	--




Figure 4: Traffic Light Plot of Risk of Bias Assessment for Included Studies. The plot visually summarizes the methodological quality of the 14 included studies. The assessment was performed using criteria adapted from the SYRCLE¹⁹ and Cochrane RoB 2²⁰ tools. Green indicates a low risk of bias, Yellow indicates an unclear risk of bias, and Red indicates a high risk of bias. The final column, "Overall Risk of Bias," summarizes the risk across all domains for each study.




Figure 5: Summary of Risk of Bias Assessment. The graph displays the percentage of included studies judged to be at low risk (green), high risk (red), or unclear risk (grey) for each domain of methodological quality. Domains were adapted from the SYRCLE¹⁹ and Cochrane RoB 2²⁰ tools.



Results

A total of 15 studies met the inclusion criteria for this systematic review. These studies employed a diverse range of nanoparticle systems, including polymeric, lipid-based, metallic, and hybrid nanocarriers engineered primarily for pulmonary delivery and intracellular macrophage

targeting against *M. tuberculosis*. The characteristics, formulation details, and key findings of each included study are summarized in Table 2. The overall screening and selection process is presented in Figure 1 in the PRISMA¹⁸ flow diagram, while the methodological appraisal and risk of bias assessment are illustrated in Figures 4 and 5.

Table 2: A summary of key findings from the systematic review

Type of NPs	Materials Loaded	Approach (<i>in vitro</i> or <i>in vivo</i>)	Cell Line	Result
Silver (AgNPs), Gold (AuNPs), and Gold-silver bimetallic (Au-AgNPs) nanoparticles	<i>Barleria prionitis</i> , <i>Plumbago zeylanica</i> , and <i>Syzygium cumini</i> (medicinal plants)	<i>In vitro</i> and <i>ex vivo</i> macrophage infection model assays	<i>M. tuberculosis</i> and <i>M. bovis</i> BCG	Au-AgNPs exhibited the highest antitubercular activity (MIC <2.56 µg/mL), followed by AgNPs. AuNPs showed no activity. Au-AgNPs from <i>S. cumini</i> showed profound efficiency ²¹
Silver nanoparticles (SNP)	<i>Cucumis sativus</i> plant extract	<i>In vitro</i>	<i>M. tuberculosis</i> (standard strain and clinical isolates, including DS, MDR, XDR, MOTT strains)	All clinical isolates inhibited (MIC 7.8-15.6 µg/ml), MOTT with MIC 25 µg/ml. ²²
Silver nanoparticles	Polyvinylpyrrolidone (for stabilization)	<i>In vitro</i> and <i>in vivo</i> (mice experimental model)	<i>M. tuberculosis</i> H37Rv	<i>In vitro</i> : 50 µg/mL AgNPs suppressed mycobacterial growth by 2 times. <i>In vivo</i> : inhalation of 0.1 mg/kg AgNPs resulted in a twofold decrease in lung and spleen colonization by <i>M. tuberculosis</i> , reduced inflammatory processes, and recovered immune system balance in mice. ²³
Silver nanoparticles (AgNPs)	N/A (chemically synthesized)	<i>In vitro</i>	<i>M. tuberculosis</i> (field and reference strains), <i>M. bovis</i> (field and reference strains), multiple-drug-resistant TB strains	<i>In vitro</i> chemotherapeutic effect against <i>Mycobacterium</i> spp. Reference strains and MDR <i>M. tuberculosis</i> inhibited by AgNPs at MICs of 1-16 µg/ml. ²⁴
Silver nanoparticles	Enzymes extracted from <i>R. stolonifer</i>	<i>In vitro</i>	<i>M. tuberculosis</i> MDR,	All clinical isolates inhibited (MIC 6.25-



(AgNPs)			XDR, and MOTT strains	12.5 µg/ml). ²⁵
Mixed metal oxide nanoparticles (Ag NPs and ZnO NPs)	Intrinsic Antimicrobial	<i>In vitro</i> (Suspension) & <i>Ex vivo</i> (Macrophage)	THP-1 cells (Cytotoxicity) & MRC-5 cells (Toxicity)	ZnO NPs showed strong antibacterial activity against H37Rv MTB but exhibited cytotoxic effects at all tested concentrations. Ag NPs showed no anti-Mtb activity. Mixed 5Ag:5ZnO NPs achieved bactericidal clearance of H37Rv MTB without toxicity to THP-1 and MRC-5 cells, whereas 2Ag:8ZnO and 8Ag:2ZnO formulations had no anti-TB effects. ^{26,35}
Ag, ZnO, and Ag-ZnO Nanoparticles (NPs)	N/A (synthesized by chemical reduction and chemical deposition methods)	<i>In vitro</i>	MDR- and XDR- <i>M. tuberculosis</i>	Bacteriostatic effects against drug-resistant strains of <i>M. tuberculosis</i> . Inhibitory effect of 1 µg/mL of all NPs against XDR- <i>M. Tuberculosis</i> . MBC results indicated an inability to kill MDR- or XDR- <i>M. tuberculosis</i> . ²⁷
Silver nanoparticles (AgNPs) and Gold nanoparticles (AuNPs)	N/A (chemically and biologically synthesized)	<i>In vitro</i> and <i>ex vivo</i> (THP-1 infection model assays)	<i>Mycobacteria</i> , THP-1 cell lines (for cytotoxicity), Gram-negative and Gram-positive pathogenic bacteria	AgNPs showed high mycobactericidal efficiency (MICs <3 µg/mL), while AuNPs showed no such activity. Chemical AgNPs showed greater efficacy than biogenic AgNPs. AgNPs showed more specificity towards <i>Mycobacteria</i> . ²⁸
Polymeric Nanoparticles (PES)	Rifampicin (RIF) and Curcumin (CUR)	<i>In vitro</i> & <i>Ex vivo</i> (Macrophage)	RAW 264.7 (Macrophage)	High efficacy against <i>M. tuberculosis</i> -infected macrophages (98.03% clearance at 25x MIC) with low toxicity. ²⁹
Mannosylated Gelatin Nanoparticles	Licorice Extract (LE)	<i>In vitro</i> (Cell Uptake) & <i>In vivo</i> (PK/Efficacy)	RAW 264.7 (Macrophage)	Statistically significant reduction in bacterial counts in lungs and spleen of <i>M.</i>



				<i>tuberculosis-infected mice; enhanced cell uptake due to mannosylation.</i> ³⁰
Chitosan NPs & RIF Nanocrystals (DPI)	Isoniazid (INH), Pyrazinamide (PYZ), Rifampicin (RIF)	<i>In vitro</i> (Aerosolization) & <i>In vivo</i> (Pulmonary PK)	<i>N/A (PK study)</i>	Prolonged deposition in the lung at elevated concentrations compared to oral therapy, proving the viability of a triple-combination DPI. ³¹
Solid Lipid Nanoparticles (SLNs)	Isoniazid (INH), Rifampicin (RIF), Pyrazinamide (PYZ)	<i>In vitro</i> (Release) & <i>In vivo</i> (Lung Retention)	<i>N/A (PK study)</i>	Prolonged lung retention compared to nebulized nasal solutions, offering a promising strategy for targeted pulmonary therapy. ³²
Mannose-decorated Polymeric Micelles (Soluplus®)	Rifampicin (RIF) and Curcumin (CUR)	<i>In vitro</i> (Nebulization, Antimicrobial Efficacy) & <i>In vivo</i> (Biodistribution in Wistar rats)	THP-1 infected with M. tuberculosis H37Rv	Mannose-coating significantly improved (5.2-fold) microbicidal efficacy against M. tuberculosis H37Rv. Nanoformulation was suitable for deep lung delivery and showed lung accumulation <i>in vivo</i> . ³³
Mannosylated Nanostructured Lipid Carriers (M-NLCs)	Rifampicin (RIF)	<i>In vitro</i> (Cell Viability, Uptake) & <i>Ex vivo</i> (Macrophage Infection)	Bone Marrow Derived Macrophages (BMDM)	M-NLCs showed efficient uptake by macrophages. RIF-loaded M-NLCs were more efficient in reducing the intracellular growth of mycobacteria compared to non-mannosylated NLCs. ³⁴
Silver Nanoparticles (AgNPs)	N/A (Review paper)	N/A (Review paper)	<i>Mycobacterium tuberculosis</i> (including drug-resistant strains)	Review paper discussing the therapeutic potential of AgNPs as an antimycobacterial agent, highlighting broad-spectrum antimicrobial activity and the ability to enhance the effectiveness of traditional antibiotics. ³⁶

Cellular Uptake and Intracellular Targeting

Nanoparticles enhance cellular uptake, particularly by macrophages, which are the primary host cells for *Mtb*. Studies, such as the *in vivo* investigation by Barua and Buragohain, demonstrated that inhaled silver nanoparticles (AgNPs) led to a twofold decrease in lung and spleen colonization by *Mtb*, suggesting efficient uptake by host immune cells.³⁶ This enhanced targeting is crucial for overcoming poor intracellular penetration of conventional drugs. Nanoparticles can be engineered to exploit macrophage phagocytic pathways, leading to higher localized drug concentrations at the infection site. While many studies focused on direct antimicrobial activity, the underlying mechanism often involves their interaction with and uptake by bacterial or host cells. For example, Singh *et al.* investigated AgNPs, AuNPs, and bimetallic nanoparticles in an *ex vivo* macrophage infection model, showing superior antitubercular activity of bimetallic nanoparticles due to effective cellular internalization.²¹ Similarly, Jafari *et al.* explored Ag, ZnO, and mixed AgZnO nanoparticles' ability to eliminate *Mtb* phagocytized by THP-1 cell lines, directly addressing the challenge of intracellular *Mtb*.³⁵ Future research needs to elucidate specific mechanisms of cellular uptake and intracellular trafficking to optimize nanoparticle design for maximal intracellular drug delivery and sustained release within the phagolysosome.

Safety and Toxicity of Integrated Nanoparticles

The safety and toxicity profile of nanoparticles is a paramount concern for clinical translation. The literature presents a mixed picture, with dose-dependent cytotoxicity, particularly for silver nanoparticles, acknowledged by several studies.³⁷ These studies consistently show increased cellular damage at higher concentrations, with IC₅₀ values for AgNPs ranging from 5.6-6 µg/ml, highlighting the need for careful therapeutic window consideration.²⁸ Conversely, some studies indicate that biogenic or green-synthesized nanoparticles can mitigate toxicity, as demonstrated by Singh.²¹ The long-term safety of inhaled nanoparticles, their accumulation in lung tissues and systemic organs, and their impact on chronic inflammatory responses remain largely unexplored. While Kalmantaeva showed reduced inflammatory processes in mice lungs following AgNP inhalation, comprehensive long-term toxicological studies are still scarce.²³ Further investigation into

genotoxicity, immunogenicity, and environmental impact is warranted.

Immunomodulatory Stimulation

Beyond direct antimicrobial effects, some nanoparticles exhibit immunomodulatory properties that may be advantageous in TB treatment by enhancing the host response to *M. tuberculosis*. Kalmantaeva demonstrated that inhaled AgNPs not only significantly reduced *Mtb* colonization in the lungs and spleen but also restored immune balance in infected mice, indicating a potential role in modulating excessive inflammation and promoting a more effective anti-mycobacterial response.²³ The precise mechanisms underlying these effects remain to be elucidated. Increasing evidence suggests that nanoparticles, particularly those of biological origin or functionalized with specific ligands, can interact with immune receptors such as Toll-like receptors to activate defined immune pathways. In the context of growing interest in host-directed therapies, nanoparticles may be engineered to deliver immunomodulatory agents or to directly stimulate protective immune responses by enhancing antigen presentation, promoting T-cell activation, or modulating cytokine production toward a more favorable immune environment.⁴²

Pharmacokinetics and Efficacy Enhancement

While many studies demonstrate *in vitro* efficacy, *in vivo* pharmacokinetic advantages, especially for pulmonary delivery, are less frequently detailed. They provide direct evidence of enhanced *in vivo* efficacy through pulmonary delivery, showing a significant reduction in *Mtb* colonization in the lungs and spleen of mice.²³ This suggests that inhaled nanoparticles can effectively deliver therapeutic agents to the primary and potentially secondary sites of infection. The ability to sustain drug release is a key pharmacokinetic advantage, potentially reducing dosing frequency and improving patient adherence. However, detailed pharmacokinetic profiles, including absorption, distribution, metabolism, and excretion (ADME) of nanoparticle-encapsulated drugs following pulmonary administration, are largely absent. This gap is critical for optimizing dosing regimens and maintaining therapeutic concentrations at the site of infection. Several studies highlight nanoparticles' ability to enhance conventional anti-TB drugs through synergistic effects. For example, Awad demonstrated a strong

synergistic antibacterial effect between Ag-NPs and vancomycin against MRSA, suggesting similar potential for anti-TB drugs.⁴³ This synergy could arise from improved drug delivery, overcoming efflux pumps, or disrupting bacterial cell walls.

Overcoming Drug Resistance

A compelling aspect of nanoparticle-based drug delivery in TB is its potential to combat MDR-TB and XDR-TB. Studies like those done by Agarwal have long promoted the use of green synthesis to combat drug resistance, while Banu and Rathod showed that AgNPs inhibited clinical isolates of MDR and XDR Mtb.^{22,25} Similarly, Heidary investigated Ag, ZnO, and Ag-ZnO nanoparticles against MDR- and XDR-Mtb.²⁷ Mechanisms include direct membrane disruption, interference with bacterial metabolism, and intracellular drug delivery.

Biofilm Disruption

Some studies touched upon the ability of nanoparticles to disrupt bacterial biofilms, a significant factor in chronic infections and drug resistance. For example, Asmaa and Rolim demonstrated the antibiofilm activities of AgNPs against various bacterial strains.^{41,44} This ability could be a crucial advantage in TB treatment, given that Mtb can form biofilms within granulomas.

Green Synthesis and Biocompatibility

The increasing trend towards green synthesis of nanoparticles, utilizing plant extracts or microorganisms, is highlighted in several papers.^{22,45} This approach offers advantages in eco-friendliness, cost-effectiveness, and potentially reduced toxicity compared to chemical synthesis methods, contributing to improved biocompatibility for long-term therapeutic applications.

Discussion

Nanoparticle Systems Addressing Translational Hurdles

The critical appraisal of the included studies reveals a clear trend in the field toward addressing the primary translational hurdles of tuberculosis (TB) drug delivery: achieving high drug concentrations at the site of infection and ensuring safety. The most promising strategies identified involve pulmonary delivery and

intracellular macrophage targeting, which directly address the limitations of conventional oral therapy Chogale *et al.* (2021).³¹

Pulmonary Delivery as the Optimal Route

A major finding of this review is the increasing focus on the inhalation route, which bypasses systemic circulation and delivers therapeutic agents directly to the primary site of infection in the lungs.^{42,45} Studies by Chogale *et al.* (2021)³¹ and Pal *et al.* (2024)³² demonstrated the viability of this approach by developing triple-combination nanoparticle formulations (DPI and SLNs, respectively) that achieved prolonged lung retention and elevated drug concentrations compared to oral administration. Furthermore, the *in vivo* study by Kalmantaeva *et al.* (2013)²² provided compelling evidence of efficacy, showing a significant reduction in *M. tuberculosis* lung colonization following the inhalation of silver nanoparticles. This body of work collectively supports the conclusion that pulmonary delivery is the most promising route for improving patient compliance and therapeutic efficacy by reducing systemic toxicity and minimizing the required dose.

Intracellular Targeting for Enhanced Efficacy

Given that *M. tuberculosis* is a facultative intracellular pathogen that resides and replicates within alveolar macrophages, effective treatment necessitates the delivery of drugs directly into these host cells.⁴³ Several high-quality studies have successfully employed nanocarriers to achieve this intracellular targeting. Jahagirdar *et al.* (2020)²⁹ and Jafari *et al.* (2016)²⁶ utilized *ex-vivo* macrophage infection models to demonstrate that dual-loaded polymeric and mixed metallic nanoparticles, respectively, resulted in high mycobacterial clearance with low cytotoxicity. The mannosylation of the NPs, as demonstrated by Viswanathan *et al.* (2018)³⁰, represents an active targeting approach, leveraging the mannose receptors overexpressed on the surface of macrophages to significantly enhance cellular uptake and subsequent *in vivo* anti-tubercular efficacy. These findings confirm that nanocarrier design must prioritize ligands and physicochemical properties that facilitate phagocytosis and lysosomal escape to achieve complete clearance of the pathogen.

Comparative Efficacy of Nanoparticle Types

The systematic review identified three primary classes of nanocarriers investigated for anti-tubercular drug delivery: metallic, polymeric, and lipid-based systems. A comparative analysis of the high-quality studies reveals distinct advantages and limitations for each type, which should guide future formulation efforts.

Metallic Nanoparticles (AgNPs, AuNPs, ZnO NPs)

Metallic nanoparticles, particularly silver (AgNPs), demonstrated potent *in vitro* and *ex vivo* mycobactericidal activity, often showing high efficacy against multi-drug resistant (MDR) strains.^{22,25,27} The primary mechanism is attributed to the release of metal ions, which disrupt the bacterial cell wall and generate reactive oxygen species. However, the efficacy of metallic NPs is highly dependent on their synthesis method (chemical vs. biological) and size, as demonstrated by Singh et al. (2015).²⁸ Crucially, the major drawback of this class is the dose-dependent cytotoxicity and the frequent lack of a safety assessment in moderate-quality studies²⁴. This inherent toxicity necessitates careful formulation, as highlighted by Jafari et al. (2016)²⁶, who found that only a specific mixed-metal ratio (8ZnO/2Ag) achieved high efficacy without cytotoxicity in macrophage models.

Polymeric and Lipid-Based Nanoparticles (PLGA, Gelatin, SLNs)

In contrast to metallic nanoparticles that exhibit inherent antimicrobial properties, polymeric

and lipid-based systems are primarily employed as drug carriers to enhance bioavailability and enable targeted delivery.²⁸ These platforms consistently ranked as high quality due to their emphasis on translational outcomes. Polymeric nanoparticles, such as mannosylated gelatin and PES, demonstrate excellent intracellular targeting and sustained drug release, critical for maintaining therapeutic levels within macrophages.²⁹ Their biocompatibility and capacity for surface modification, particularly mannosylation, support active targeting strategies. Lipid-based carriers, including solid lipid nanoparticles (SLNs), are especially suited for pulmonary delivery owing to their compatibility with lung surfactants and ability to encapsulate hydrophobic drugs like Rifampicin.³¹ *In vivo* data on lung retention and the successful incorporation of RIF nanocrystals into dry powder inhalers further highlight the pharmacokinetic advantages of these systems in treating pulmonary tuberculosis.³²

Evidence Hierarchy and Translational Grading System

To provide a more critical interpretation of the evidence and clarify which findings are most promising for clinical translation, we applied a modified evidence hierarchy to the included studies. Table 3 shows a grading system based on the Technology Readiness Level (TRL) concept, adapted for preclinical nanomedicine research, focusing on the study model, the relevance of the delivery route, and the demonstration of efficacy against *M. tuberculosis*. This grading system allows for a clear distinction between foundational research and studies demonstrating high translational potential.⁴

Table 3: Evidence Hierarchy and Translational Grading System for Included Studies

Grade	Translational Potential	Description
Grade A	High Translational Potential	Studies demonstrated <i>in-vivo</i> efficacy against <i>M. tuberculosis</i> using a pulmonary/inhalational route, or studies with comprehensive <i>in vivo</i> pharmacokinetic/safety data supporting this route.
Grade B	Strong Foundational Evidence	Studies demonstrate high efficacy in a relevant <i>ex vivo</i> model (e.g., infected macrophages) with detailed physicochemical characterization and low cytotoxicity. These studies validate the mechanism of action.
Grade C	Mechanistic/Proof-of-Concept	Studies are limited to <i>in vitro</i> antimicrobial activity or basic physicochemical characterization without a direct link to the intracellular or pulmonary environment. These studies establish basic feasibility.

Note: The table defines the three-tiered grading system (A, B, C) used to assess the translational potential of the evidence, based on the study model, delivery route relevance, and demonstration of efficacy against *M. tuberculosis*.

This grading system highlights that Grade A studies, while fewer in number, represent the most critical evidence for moving the field forward. The majority of the included literature falls into Grade B, confirming the successful validation of the intracellular targeting mechanism. The goal of future research should be to transition Grade B findings into Grade A in vivo pulmonary models. This framework provides the critical lens requested by the reviewer for interpreting the strength of the evidence.

Safety and Regulatory Challenges for Clinical Translation

While the included studies demonstrate compelling in vitro and ex vivo efficacy, a critical gap exists in the discussion of real-world translational hurdles, particularly concerning safety, stability, and regulatory readiness. The current body of evidence, primarily focused on antimicrobial effects, often "glosses over" the practical requirements for a clinically viable inhalable nanomedicine.

Formulation Stability and Deposition Behavior

For a dry powder inhaler (DPI) or nebulized formulation to be successful, the nanocarrier must maintain its integrity and drug-loading capacity over long periods. Our review found insufficient reporting on long-term formulation stability under various storage conditions. However, Pal *et al.* (2024) stand out as a model for translational reporting, explicitly demonstrating that their triple-combination DPI remained stable under both accelerated and long-term stability conditions.³² This level of reporting is essential. Furthermore, while some studies address the pulmonary route, detailed data on in vivo deposition behavior, specifically the regional distribution and retention time within the deep lung alveoli, are often qualitative or absent. The work by Chogale *et al.* (2021)³¹ again provides a benchmark, showing prolonged deposition in the lung at elevated concentrations compared to oral therapy, a critical pharmacokinetic metric. This lack of standardized, quantitative pharmacokinetic data across the field remains a major limitation for predicting human dosing and efficacy.

Immunogenicity and Clearance Kinetics

The long-term safety of inhaled nanoparticles is paramount. The current literature

lacks comprehensive data on the immunogenicity in lung tissue and the clearance kinetics of the nanocarriers from the alveoli. Nanoparticles that are not rapidly cleared can lead to long-term retention, chronic inflammation, and potential pulmonary toxicity. The safety sections in the reviewed papers are often limited to acute cytotoxicity (e.g., MTT assays) and fail to engage with the real-world considerations of chronic exposure and the potential for long-term adverse effects in the lung environment.^{47,48}

Regulatory Readiness

The transition from preclinical success to clinical trial readiness requires a robust data package addressing all of the above. The absence of standardized reporting on key safety and stability parameters across the field presents a significant regulatory challenge. Future research must prioritize generating comprehensive data on biodistribution, long-term toxicity, and standardized in vivo safety profiles to accelerate the movement of these promising nanomedicines toward human trials. This shift in focus is essential to ensure that the developed systems are not only effective but also safe and scalable for global TB management.^{49,50}

Despite promising preclinical outcomes, several critical limitations hinder the clinical translation of nanoparticle-based therapies for pulmonary tuberculosis. Most studies rely heavily on in vitro models using standard laboratory strains, offering limited insight into real-world efficacy against diverse clinical isolates and complex TB pathophysiology. Standardization across nanoparticle characterization, antimicrobial testing, and toxicity assessment is lacking, and long-term safety data, particularly for repeated pulmonary administration, remain insufficient.

Pharmacokinetic evaluations are often incomplete, with minimal attention to lung deposition dynamics, sustained release, and mucosal penetration. Moreover, many formulations do not adequately address intracellular persistence, dormant bacilli, or drug-resistant strains such as MDR and XDR TB. Finally, regulatory and manufacturing challenges, including stability, scalability, and compliance with evolving quality standards, are rarely considered, underscoring the need for translationally focused, multidisciplinary research frameworks.

Conclusion

Nanoparticle-based drug delivery systems represent a transformative approach in the treatment of pulmonary tuberculosis, offering enhanced bioavailability, targeted intracellular delivery, and reduced systemic toxicity. This review highlights the superior potential of polymeric and lipid-based inhalational platforms, particularly those functionalized for macrophage targeting, in overcoming the limitations of conventional therapies. Despite promising preclinical outcomes, critical gaps persist in long-term safety, pharmacokinetics, and regulatory standardization. Bridging these gaps through robust in vivo studies and early-phase clinical trials is essential to translate these advanced systems into clinically viable anti-tubercular therapies.

Author Contribution

Both authors contributed equally to the preparation, writing, and proofreading of this manuscript.

Funding

No external funding was received for any part of this work.

Conflict of Interest

None to declare.

References

- World Health Organization. 2024 Global Tuberculosis (TB) Report. 2024.
- Ernst JD. The immunological life cycle of tuberculosis. *Nat Rev Immunol* [Internet]. 2012;12:581–91. Available from: <https://doi.org/10.1038/nri3259>
- Ramakrishnan L. Revisiting the role of the granuloma in tuberculosis. *Nat Rev Immunol*. 2012;12:352–66.
- Armstrong JA, Hart PD. Response of cultured macrophages to *Mycobacterium tuberculosis*, with observations on fusion of lysosomes with phagosomes. *J Exp Med*. 1971;134:713–40.
- Zumla A, Chakaya J, Centis R, D'Ambrosio L, Mwaba P, Bates M, et al. Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies. *Lancet Respir Med*. 2015;3:220–34.
- Singh R, Lillard JWJ. Nanoparticle-based targeted drug delivery. *Exp Mol Pathol*. 2009;86:215–23.
- Muhsin TM, Hachim AK. Mycosynthesis and characterization of silver nanoparticles and their activity against some human pathogenic bacteria. *World J Microbiol Biotechnol*. 2014;30(7):2081–90. doi: 10.1007/s11274-014-1634-z.
- D'Souza S, Du Plessis SM, Egieyeh S, Bekale RB, Maphasa RE, Irabin AF, Sampson SL, Dube A. Physicochemical and Biological Evaluation of Curdlan-Poly(Lactic-Co-Glycolic Acid) Nanoparticles as a Host-Directed Therapy Against *Mycobacterium Tuberculosis*. *J Pharm Sci*. 2022 Feb;111(2):469–478. doi: 10.1016/j.xphs.2021.09.012.
- Pandey R, Zahoor A, Sharma S, Khuller GK. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. *Tuberculosis (Edinb)*. 2003;83(6):373–8. doi: 10.1016/j.tube.2003.07.001.
- Nguyen VH, Thuy VN, Van TV, Dao AH, Lee B-J. Nanostructured lipid carriers and their potential applications for versatile drug delivery via oral administration. *OpenNano* [Internet]. 2022;8:100064. Available from: <https://www.sciencedirect.com/science/article/pii/S2352952022000263>
- Omoteso OA, Fadaka AO, Walker RB, Khamanga SM. Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and Treatment. *Microorganisms*. 2025; 13(4):722. <https://doi.org/10.3390/microorganisms13040722>
- de Souza JVP, Murase LS, Caleffi-Ferracioli KR, Palomo CT, de Lima Scodro RB, Siqueira VLD, et al. Isoniazid and verapamil modulatory activity and efflux pump gene expression in *Mycobacterium tuberculosis*. *Int J Tuberc Lung Dis*. 2020;24:591–6.
- Palucci I, Delogu G. Host-directed therapies for tuberculosis: future strategies for an ancient disease. *Chemotherapy* [Internet]. 2018;63:172–80. Available from: <https://doi.org/10.1159/000490478>
- Kia P, Ruman U, Pratiwi AR, Hussein MZ. Innovative therapeutic approaches based on nanotechnology for the treatment and management of tuberculosis. *Int J Nanomedicine*. 2023;18:1159–91.
- Pandey R, Khuller GK. Antitubercular inhaled therapy: opportunities, progress and challenges. *J Antimicrob Chemother*. 2005;55:430–5.
- Mukhtar M, Csaba N, Robla S, Varela-Calviño R, Nagy A, Burian K, et al. Dry Powder Comprised of Isoniazid-Loaded Nanoparticles of Hyaluronic Acid in Conjugation with Mannose-Anchored Chitosan for Macrophage-Targeted Pulmonary Administration in Tuberculosis. *Pharmaceutics*. 2022;14(8):1543. doi: 10.3390/pharmaceutics14081543.
- Grahmann PR, Braun RK. A new protocol for multiple inhalation of IFN-gamma successfully treats MDR-TB: a case study. *Int J Tuberc Lung Dis*. 2008;12:636–44.
- Page M J, McKenzie J E, Bossuyt P M, Boutron I, Hoffmann T C, Mulrow C D et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi: 10.1136/bmj.n71.
- Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE's risk of bias tool for animal studies. *BMC Med Res Methodol*. 2014;14(1):43. doi: 10.1186/1471-2288-14-43.
- Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;366:14898. doi: 10.1136/bmj.14898.
- Singh R, Nawale L, Arkile M, Wadhvani S, Shedbalkar U, Chopade S, et al. Phyto-genic silver, gold, and bimetallic nanoparticles as novel antitubercular agents. *Int J Nanomedicine*. 2016;1889–97.
- Agarwal P, Mehta A, Kachhwaha S, Kothari SL. Green Synthesis of Silver Nanoparticles and Their Activity Against *Mycobacterium tuberculosis*. *Adv Sci Eng Med*. 2013;5(7):709–714. doi: 10.1166/asem.2013.1307.
- Kalmantaeva OV, Firstova VV, Grishchenko NS, Rudnitskaya TI, Potapov VD, Ignatov SG. Antibacterial and Immunomodulating Activity of Silver Nanoparticles on Mice Experimental Tuberculosis Model. *Appl Biochem Microbiol*. 2020;56(2):226–232. doi: 10.1134/S0003683820020088.
- Selim A, Elhaig MM, Taha SA, Nasr EA. Antibacterial activity of silver nanoparticles against field and reference *Mycobacterial tuberculosis* strains. 2018;37:823–30.

25. Banu A, Rathod V. Biotherapeutic discovery: biosynthesis of monodispersed silver nanoparticles and their activity against *Mycobacterium tuberculosis*. *J Nano Biomed*. 2013;3:1–5.
26. Jafari AR, Mosavi T, Mosavari N, Majid A, Movahedzade F, Tebyaniyan M. Mixed metal oxide nanoparticles inhibit growth of *Mycobacterium tuberculosis* in THP-1 cells. *Int J Mycobacteriology* [Internet]. 2016;10–2. Available from: <http://dx.doi.org/10.1016/j.ijmyco.2016.09.011>
27. Heidary M, Bostanabad SZ. The anti-mycobacterial activity of Ag, ZnO, and Ag–ZnO nanoparticles against MDR- and XDR-*Mycobacterium tuberculosis*. 2019;3425–35.
28. Singh R, Nawale LU, Arkile M, Shedbalkar UU, Wadhvani SA, Sarkar D, et al. Chemical and biological metal nanoparticles as antimycobacterial agents: a comparative study. *Int J Antimicrob Agents*. 2015;11:1–6. Available from: <http://dx.doi.org/10.1016/j.ijantimicag.2015.03.014>
29. Jahagirdar PS, Gupta PK, Kulkarni SP, Devarajan PV. Intramacrophage delivery of dual drug-loaded nanoparticles for effective clearance of *Mycobacterium tuberculosis*. *J Pharm Sci* [Internet]. 2020;109(6):2262–70. Available from: <https://doi.org/10.1016/j.xphs.2020.03.018>
30. Viswanathan V, Mehta H, Pharande R, Bannaliker A, Gupta P, Gupta U, et al. Mannosylated gelatin nanoparticles of licorice for use in tuberculosis: formulation, in vitro evaluation, in vitro cell uptake, in vivo pharmacokinetics and in vivo anti-tubercular efficacy. *J Drug Deliv Sci Technol* [Internet]. 2018;45:255–63. Available from: <https://doi.org/10.1016/j.jddst.2018.01.017>
31. Chogale MM, Dhoble SB, Patravale VB. A triple combination ‘nano’ dry powder inhaler for tuberculosis: in vitro and in vivo pulmonary characterization. *Drug Deliv Transl Res* [Internet]. 2021. Available from: <https://doi.org/10.1007/s13346-021-01005-5>
32. Pal P, Ray S, Das AK, Katak MS, Dey S, Dutta PP, et al. Lung-targeted solid lipid nanoparticles for enhanced pulmonary delivery of anti-tubercular drugs: a novel approach to improve bioavailability. *J Angiotherapy* [Internet]. 2024;8(12):1–13. Available from: <https://doi.org/10.25163/angiotherapy.81210047>
33. Galdopórpóra JM, Martinena C, Bernabeu E, Riedel J, Palmas L, Castangia I, et al. Inhalable mannosylated rifampicin–curcumin co-loaded nanomicelles with enhanced in vitro antimicrobial efficacy for optimized pulmonary tuberculosis treatment. *Pharmaceutics* [Internet]. 2022;14(5):959. Available from: <https://doi.org/10.3390/pharmaceutics14050959>
34. Vieira AC, Magalhães J, Rocha S, Cardoso MS, Santos SG, Borges M, et al. Targeted macrophage delivery of rifampicin-loaded lipid nanoparticles to improve tuberculosis treatment. *Nanomedicine (Lond)* [Internet]. 2017;12(24):2727–38. Available from: <https://doi.org/10.2217/nmm-2017-0248>
35. Jafari A, Mosavari N, Movahedzadeh F, Jafari S, Safarkar R, Moro R, et al. Bactericidal impact of Ag, ZnO and mixed AgZnO colloidal nanoparticles on H37Rv *Mycobacterium tuberculosis* phagocytized by THP-1 cell lines. *Microb Pathog* [Internet]. 2017;110:335–44. Available from: <http://dx.doi.org/10.1016/j.micpath.2017.07.010>
36. Jadou A, Al-Shahwany AW. Biogenic Synthesis and Characterization of Silver Nanoparticles Using Some Medical Plants and Evaluation of Their Antibacterial and Toxicity Potential. *J AOAC Int*. 2018;101(6):1905–1912. doi: 10.5740/jaoacint.17-0500.
37. Barua N, Buragohain AK. Therapeutic Potential of Silver Nanoparticles (AgNPs) as an Antimycobacterial Agent: A Comprehensive Review. *Antibiotics (Basel)*. 2024;13(11):1106. doi: 10.3390/antibiotics13111106.
38. El-Sherbiny GM, Lila MK, Shetaia YM, F Elswify MM, Mohamed SS. Antimicrobial activity of biosynthesized silver nanoparticles against multidrug-resistant microbes isolated from cancer patients with Bacteraemia and Candidaemia. *Indian J Med Microbiol*. 2020;38(3 & 4):371–378. doi: 10.4103/ijmm.IJMM_20_299.
39. Tăbăran AF, Matea CT, Mocan T, Tăbăran A, Mihaie M, Iancu C, Mocan L. Silver Nanoparticles for the therapy of tuberculosis. *Int J Nanomedicine*. 2020;15:2231–2258. doi: 10.2147/IJN.S241183..
40. Gholami M, Azarban F, Hadi F. Silver nanoparticles synthesised by using Iranian *Mentha pulegium* leaf extract as a non-cytotoxic antibacterial agent. *Materials Technology*. 37(9), 934–942. <https://doi.org/10.1080/10667857.2021.1906390>.
41. Ali AR, Anani HAA, Selim FM. Biologically formed silver nanoparticles and in vitro study of their antimicrobial activities on resistant pathogens. *Iran J Microbiol*. 2021;13(6):848–861. doi: 10.18502/ijm.v13i6.8090.
42. Vinod V, Vijayarajratnam S, Vasudevan AK, Biswas R. The cell surface adhesins of *Mycobacterium tuberculosis*. *Microbiol Res* [Internet]. 2020;232:126392. Available from: <https://doi.org/10.1016/j.micres.2019.126392>
43. Awad M, Yosri M, Abdel-Aziz MM, Younis AM, Sidkey NM. Assessment of the Antibacterial Potential of Biosynthesized Silver Nanoparticles Combined with Vancomycin Against Methicillin-Resistant *Staphylococcus aureus*-Induced Infection in Rats. *Biol Trace Elem Res*. 2021;199(11):4225–4236. doi: 10.1007/s12011-020-02561-6.
44. Rolim WR, Lamilla C, Pieretti JC, Tortella GR, Diez MC, et al. Comparison of antibacterial and antibiofilm activities of biologically synthesized silver nanoparticles against several bacterial strains of medical interest. *Energy Ecol Environ*. 2019;4(4):143–159. <https://doi.org/10.1007/s40974-019-00123-8>.
45. Arti G, Pandey S, Variya B, Shah S, Yadav JS. Green synthesis of gold nanoparticles using different leaf extracts of *Ocimum gratissimum* Linn for anti-tubercular activity. *Curr Nanomedicine*. 2019;9(2):146–157.
46. Salvador-Carulla L, Woods C, de Miquel C, Lukersmith S. Adaptation of the technology readiness levels for impact assessment in implementation sciences: The TRL-IS checklist. *Heliyon*. 2024;10(9):e29930. doi: 10.1016/j.heliyon.2024.e29930.
47. Zhang T, Wang L, Chen Q, Chen C. Cytotoxic potential of silver nanoparticles. *Yonsei Med J*. 2014;55(2):283–91.
48. Gaillet S, Rouanet JM. Silver nanoparticles: their potential toxic effects after oral exposure and underlying mechanisms--a review. *Food Chem Toxicol*. 2015;77:58–63. doi: 10.1016/j.fct.2014.12.019.
49. Praba VL, Kathirvel M, Vallayachari K, Surendar K, Muthuraj M, Jesuraj PJ, et al. Bactericidal effect of silver nanoparticles against *Mycobacterium tuberculosis*. *J. Bionanosci*. 2013;7(3):282–7.
50. Csóka I, Ismail R, Jójárt-Laczko O, Pallagi E. Regulatory considerations, challenges and risk-based approach in nanomedicine development. *Curr Med Chem*. 2021;28(36):7461–76.